Entera Bio secures financing to extend runway and advance EB613 toward FDA
Entera Bio announced a financing package to extend its cash runway to 2030 and fund EB613’s Phase 3 toward an FDA filing. The plan includes roughly 122.96 million ordinary shares and up to 11.84 million pre-funded warrants priced at $2.04, led by BVF Partners, who will gain two board seats. While the deal improves liquidity and optionality, it raises dilution concerns and leaves near-term price action vulnerable to earnings and market momentum.
View signal analysis